Shionogi is one of Japan's leading research-based pharmaceutical companies, with a heritage in infectious disease, pain management, and psychiatry. The company gained international attention for its COVID-19 antiviral treatment development and has continued to build a pipeline focused on infectious diseases and central nervous system disorders.

For international investors, Shionogi offers exposure to a focused Japanese pharma company with strong capabilities in anti-infective drug development — an area of growing global public health relevance. The company's commitment to infectious disease research, including influenza and emerging viral threats, positions it as a strategically important participant in pandemic preparedness efforts, while its established domestic franchise provides a stable earnings base to support ongoing R&D investment.